晚期胃癌化疗对血浆miR-21、let-7i表达水平影响的研究

发布时间：2018-03-06 22:30

本文选题：miR-21　切入点：let-7i　出处：《青海大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:本研究旨在探索晚期胃癌患者血浆miR-21、let-7i表达水平与健康对照人群是否存在差异,探索血浆miR-21、let-7i表达水平与XELOX方案化疗疗效、疾病进展的相关性研究。方法:收集初治晚期胃癌患者病例60例,均接受XELOX方案化疗,每2周期化疗后进行疗效评价,未出现疾病进展者继续原方案化疗,分别在接受化疗前、2周期化疗后、疾病进展时制备血浆样本,同期制备60例健康对照人群血浆样本。所有血浆样本行Q-PCR检测miR-21、let-7i表达。进行统计学分析miR-21、let-7i表达水平及其与化疗疗效、疾病进展的相关性。结果:1.晚期胃癌患者较健康对照人群血浆miR-21表达量明显上调,差异有统计学意义(P0.01);晚期胃癌患者与健康对照人群血浆let-7i表达量变化不明显(P=0.782),差异无统计学意义。2.晚期胃癌患者化疗前后miR-21表达量明显下调(P0.01),差异有统计学意义;let-7i在化疗前后变化不明显,差异无统计学意义(P=0.568)。3.晚期胃癌患者有效组化疗前后miR-21表达量明显下调,差异有统计学意义(P0.01)。晚期胃癌患者无效组化疗前后miR-21表达变化不明显,差异无统计学意义(P=0.54)。化疗无效组化疗前患者血浆miR-21相对表达量高于有效组,差异有统计学意义(P0.01)。4.化疗有效组疾病进展时血浆miR-21相对表达量高于化疗前(P0.01),并高于化疗后(P0.01),化疗无效组疾病进展时血浆miR-21相对表达量高于化疗前(P0.01),并高于化疗后(P0.01)。结论:血浆miR-21水平可能用于预测晚期胃癌患者使用XELOX化疗方案的疗效及疾病进展。
[Abstract]:Objective: to explore whether the expression of miR-21 let-7i in patients with advanced gastric cancer is different from that in healthy controls, and to explore the expression of miR-21 let-7i in patients with advanced gastric cancer and the efficacy of XELOX regimen chemotherapy. Methods: 60 patients with advanced gastric cancer were treated with XELOX regimen chemotherapy. The therapeutic effect was evaluated after 2 cycles of chemotherapy. Plasma samples were prepared after 2 cycles of chemotherapy before and after the disease progressed. The expression of miR-21 let-7i in all plasma samples was detected by Q-PCR. The expression level of miR-21 let-7i and its effect on chemotherapy were analyzed statistically. Results: 1. Plasma miR-21 expression in patients with advanced gastric cancer was significantly higher than that in healthy controls. There was no significant difference in plasma let-7i expression between patients with advanced gastric cancer and healthy controls, but there was no significant difference between them. 2.The expression of miR-21 in patients with advanced gastric cancer decreased significantly before and after chemotherapy, and the difference was statistically significant. The changes of let-7i were not obvious before and after chemotherapy. There was no significant difference in the expression of miR-21 before and after chemotherapy in patients with advanced gastric cancer. The difference was statistically significant (P 0.01). There was no significant change in the expression of miR-21 before and after chemotherapy in the ineffective group of patients with advanced gastric cancer. There was no significant difference between the two groups. The relative expression of plasma miR-21 was higher in the ineffective group than in the effective group. The relative expression of plasma miR-21 in chemotherapeutic effective group was higher than that before chemotherapy, and higher than that after chemotherapy. The relative expression of plasma miR-21 in ineffective group was higher than that before chemotherapy and after chemotherapy. Conclusion: plasma miR-21 level may be used to predict the therapeutic effect and disease progression of patients with advanced gastric cancer using XELOX chemotherapy regimen.
【学位授予单位】：青海大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735.2

【相似文献】